Received Feb 25, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAPHEPBIP | DTAP + HEPB + IPV (PEDIARIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | TC47K | — |
wrong vaccine administered; This non-serious case was reported by a other health professional via call center representative and described the occurrence of wrong vaccine administered in a 22-month-old male patient who received DTPa-HBV-IPV (Pediarix) (batch number TC47K) for prophylaxis. Co-suspect products included DTPa (DTaP vaccine) for prophylaxis. On 17-FEB-2026, the patient received the 1st dose of Pediarix. On 17-FEB-2026, an unknown time after receiving Pediarix the patient experienced wrong vaccine administered (Verbatim: wrong vaccine administered). The outcome of the wrong vaccine administered was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 18-FEB-2026 and 19-FEB-2026 The medical assistant reported that they did not initially know the brand name of the vaccine that was wrongly administered, it was later confirmed to be Pediarix based on the lot number provided. The vaccine that had been intended for administration was Tdap, but the medical assistant did not know the brand name of the intended product and could not confirm whether it had been Boostrix. The medical assistant also stated that this was the first dose of all three components of Pediarix. The reporter was informed that Pediarix contained DTaP rather than Tdap, and the HCP confirmed that Pediarix had been the vaccine involved in this incident. At one point it was reported that the intended vaccine had been Tdap, elsewhere it was noted that the intended vaccine had been DTaP instead of Tdap. The medical assistant also mentioned during the first call that the vaccine administered had included the polio virus and the Hepatitis B components.